AI conjures proteins that speed up chemical reactions

For the first time, scientists have used machine learning to create brand-new enzymes, which are proteins that accelerate chemical reactions. This is an important step in the field of protein design as new enzymes could have many uses across medicine and industrial manufacturing.

"Living organisms are remarkable chemists. Rather than relying on toxic compounds or extreme heat, they use enzymes to break down or build up whatever they need under gentle conditions. New enzymes could put renewable chemicals and biofuels within reach," said senior author David Baker, professor of biochemistry at the University of Washington School of Medicine and recipient of the 2021 Breakthrough Prize in Life Sciences.

As reported Feb, 22 in the journal Nature, a team based at the Institute for Protein Design at UW Medicine devised machine-learning algorithms that can create light-emitting enzymes called luciferases. Laboratory testing confirmed that the new enzymes can recognize specific chemicals and emit light very efficiently. This project was led by two postdoctoral scholars in the Baker Lab, Andy Hsien-Wei Yeh and Christoffer Norn.

To create new luciferase enzymes, the team first selected chemicals called luciferins that they wanted the proteins to act upon. They then used software to generate thousands of possible protein structures that might react with those chemicals.

During laboratory testing, the researchers identified an efficient enzyme, dubbed LuxSit (Let there be light). The enzyme performed the desired chemical reaction. Refinement of the enzyme led to dramatic improvements in performance. An optimized enzyme, dubbed LuxSit-i, generated enough light to be visible to the naked eye. It was found to be brighter than the natural luciferase enzyme found in the glowing sea pansy Renilla reniformis.

"We were able to design very efficient enzymes from scratch on the computer, as opposed to relying on enzymes found in nature. This breakthrough means that custom enzymes for almost any chemical reaction could, in principle, be designed," said Yeh.

New enzymes could benefit biotechnology, medicine, environmental remediation, and manufacturing. For example, in biotechnology, enzymes can improve biofuel production, food processing, and pharmaceutical manufacturing. In medicine, enzymes can serve as therapeutic and diagnostic tools. Enzyme design can improve the environment by breaking down pollutants or cleaning up contaminated sites. And enzymes may also aid in the production of new materials such as biodegradable plastics and adhesives.

This research was led by UW School of Medicine scientists and included collaborators at the University of California, Los Angeles.

This work was supported by the Howard Hughes Medical Institute, National Institutes of Health (K99EB031913), United World Antiviral Research Network, National Institute of Allergy and Infectious Disease (1 U01 AI151698-01), Audacious Project at the Institute for Protein Design, Open Philanthropy Project Improving Protein Design Fund, Novo Nordisk Foundation (NNF18OC0030446), National Science Foundation (CHE-1764328, OCI-1053575), and Eric and Wendy Schmidt by recommendation of the Schmidt Futures program. National Natural Science Foundation of China (22103060) provided partial computational resources.

Yeh AH, Norn C, Kipnis Y, Tischer D, Pellock SJ, Evans D, Ma P, Lee GR, Zhang JZ, Anishchenko I, Coventry B, Cao L, Dauparas J, Halabiya S, DeWitt M, Carter L, Houk KN, Baker D.
De novo design of luciferases using deep learning.
Nature. 2023 Feb;614(7949):774-780. doi: 10.1038/s41586-023-05696-3

Most Popular Now

Discovery of anti-cancer chemistry makes skullcap …

The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chin...

AMJEVITA™ (adalimumab-atto), first biosimilar to H…

Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States. AMJEVITA was the first bios...

Pfizer reports record full-year 2022 results

Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance. Full-year 2022 revenues of $100...

CHMP recommends Bayer’s darolutamide for the treat…

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor (ARi), plus A...

2022 Otto Bayer Award goes to Professor Frank Glor…

The Bayer Foundation has presented the Otto Bayer Award, complete with its prize money of 75,000 euros, to Professor Frank Glorius. The research scientist at the Universi...

Keys to making immunotherapy work against pancreat…

A new study that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strat...

Researchers discover causal mechanism behind rare …

Researchers from Charité - Universitätsmedizin Berlin, the Max Planck Institute for Molecular Genetics (MPIMG), and the University Hospital Schleswig-Holstein (UKSH) have...

Transforming the way cancer vaccines are designed …

A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology (IIN) at North...

Antidepressants used for chronic pain on the rise…

New research has found some antidepressants may be effective in treating certain chronic pain conditions, but others lack convincing evidence on their effectiveness. M...

Scientists pinpoint protein that helps cancer-caus…

The viruses Kaposi sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) have been linked to several cancers. For the first time, UNC School of Medicine scie...

GSK announces results from 17-year retrospective s…

GSK plc (LSE/NYSE: GSK) announced results from a retrospective study on clinical trial diversity, investigating the historical representation of US-based participants in ...

HUS Helsinki University Hospital is leading the re…

The EU has awarded a 6.55 million EUR funding to a HUS Helsinki University Hospital-led consortium to examine the mechanisms behind the long-term effects of a COVID-19 ...